Dr. Reinhard Ortmann
QIAGEN
Reinhard Ortmann is Director Oncology & Precision Diagnostics at QIAGEN and focuses on companion diagnostic commercialization. He is responsible for early companion diagnostic and drug launch preparation and alignment with QIAGEN’s pharmaceutical partners. Reinhard worked for many years in pharmaceutical companies, such as Johnson & Johnson and Chiron Biopharmaceutical, and held various sales and marketing positions covering multiple therapeutic areas. After joining the QIAGEN headquarters in Hilden/Düsseldorf in 2010, he established a number of collaborations between QIAGEN’s sales, marketing, medical and reimbursement teams with the equivalent teams in pharmaceutical companies.
Reinhard holds a Doctor of Veterinary Medicine degree and is a Graduate Economist.
Reinhard Ortmann is responsible for early companion diagnostic and drug launch preparation and alignment with QIAGEN’s pharmaceutical partners. He worked for many years in pharmaceutical companies and held various sales and marketing positions covering multiple therapeutic areas. At QIAGEN he established a number of collaborations between QIAGEN’s sales, marketing, medical and reimbursement teams with the equivalent teams in pharmaceutical companies. Reinhard holds a Doctor of Veterinary Medicine degree and is a Graduate Economist.
September 21
We have been collaborating with pharmaceutical partners for more than 15 years to develop companion diagnostics (CDx). We got 10 PMA approvals granted by the FDA and registered and commercialized the CDx assays globally in all target markets of pharma. A broad technology portfolio including qPCR, digital PCR, and NGS is available to meet any CDx requirement, building on tissue and liquid biopsies with the highest sensitivities. Starting at translational medicine, a drug development program that requires a companion diagnostic can still be complex. We need to reduce this complexity to de-risk the clinical drug-diagnostic development program and facilitate immediate patient access to testing when new drugs and tests come to market.
September 28
We have been collaborating with pharmaceutical partners for more than 15 years to develop companion diagnostics (CDx). We got 10 PMA approvals granted by the FDA and registered and commercialized the CDx assays globally in all target markets of pharma. A broad technology portfolio including qPCR, digital PCR, and NGS is available to meet any CDx requirement, building on tissue and liquid biopsies with the highest sensitivities. Starting at translational medicine, a drug development program that requires a companion diagnostic can still be complex. We need to reduce this complexity to de-risk the clinical drug-diagnostic development program and facilitate immediate patient access to testing when new drugs and tests come to market.